# CDKN2B

Source: https://onco.cc/targets/cdkn2b/  
OnCo record `cdkn2b` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.

## Summary

Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.

CIViC holds 8 clinical evidence items and 0 assertions across 5 variants, naming Palbociclib, Trametinib, Bevacizumab and Vemurafenib and others. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.76, literature 0.98, genetic association 0.70, somatic mutation 0.62).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cyclin dependent kinase inhibitor 2B; Cyclin-dependent kinase 4 inhibitor B; P15; MTS2; INK4B; TP15; CDK4I; p15INK4b
- Tags: cancer-genes-wave
- Symbol: CDKN2B
- Class: other
- Biology: Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. Location: Cytoplasm (UniProt). Locus 9p21.3 (HGNC).
- Where found: Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Renal cell carcinoma: CIViC evidence names this disease; Breast cancer: Open Targets association 0.60 with breast cancer (MONDO_0007254); Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898); Biliary tract cancer: CIViC evidence names this disease; Ewing sarcoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 9 therapies; CIViC holds 8 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ganglioglioma.

## Sources

- HGNC HGNC:1788: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1788
- UniProt P42772: https://www.uniprot.org/uniprotkb/P42772/entry
- NCBI Gene 1030: https://www.ncbi.nlm.nih.gov/gene/1030
- Ensembl ENSG00000147883: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147883

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- pathways: [Small cell lung cancer (KEGG map)](https://onco.cc/pathways/sclc-signalling/)

---
JSON: https://onco.cc/api/v1/entities/cdkn2b.json